Prudential Financial Inc. Grows Stock Holdings in Inogen, Inc. (NASDAQ:INGN)

Prudential Financial Inc. lifted its position in Inogen, Inc. (NASDAQ:INGN) by 141.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 360,002 shares of the medical technology company’s stock after purchasing an additional 210,961 shares during the quarter. Prudential Financial Inc. owned 1.51% of Inogen worth $3,301,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. AlphaQuest LLC bought a new position in shares of Inogen during the fourth quarter valued at about $43,000. American Century Companies Inc. grew its position in Inogen by 10.2% during the 4th quarter. American Century Companies Inc. now owns 54,856 shares of the medical technology company’s stock worth $503,000 after acquiring an additional 5,089 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Inogen by 13.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 42,137 shares of the medical technology company’s stock worth $409,000 after purchasing an additional 5,131 shares during the period. Geode Capital Management LLC lifted its position in Inogen by 1.1% in the third quarter. Geode Capital Management LLC now owns 554,191 shares of the medical technology company’s stock valued at $5,377,000 after purchasing an additional 5,921 shares during the last quarter. Finally, Quarry LP purchased a new stake in shares of Inogen during the third quarter valued at approximately $59,000. 89.94% of the stock is currently owned by institutional investors.

Inogen Trading Up 3.6 %

NASDAQ INGN opened at $7.20 on Thursday. The stock’s fifty day moving average price is $9.18 and its 200-day moving average price is $9.44. The stock has a market cap of $193.59 million, a P/E ratio of -3.20 and a beta of 1.16. Inogen, Inc. has a 12 month low of $6.14 and a 12 month high of $13.33.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on INGN. StockNews.com lowered shares of Inogen from a “buy” rating to a “hold” rating in a report on Wednesday, February 26th. Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a research report on Wednesday, February 26th.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.